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Mitochondrial uncoupling protein 2 (UCP2) has been well characterized to control the production of
reactive oxygen species (ROS) and astrocytes are the major cells responsible for the ROS production and
the inﬂammatory responses in the brain. However, the function of UCP2 in astrocytes and the con-
tribution of astrocytic UCP2 to depression remain undeﬁned. Herein, we demonstrated that UCP2
knockout (KO) mice displayed aggravated depressive-like behaviors, impaired neurogenesis, and en-
hanced loss of astrocytes in the chronic mild stress (CMS)-induced anhedonia model of depression. We
further found that UCP2 ablation signiﬁcantly enhanced the activation of the nod-like receptor protein 3
(NLRP3) inﬂammasome in the hippocampus and in astrocytes. Furthermore, UCP2 deﬁciency promoted
the injury of mitochondria, the generation of ROS and the physical association between thioredoxin-
interacting protein (TXNIP) and NLRP3 in astrocytes. Moreover, transiently expressing exogenous UCP2
partially rescued the deleterious effects of UCP2 ablation on the astrocytes. These data indicate that UCP2
negatively regulates the activation of NLRP3 inﬂammasome and inhibited the ROS-TXNIP-NLRP3 path-
way in astrocytes. Collectively, our ﬁndings reveal that UCP2 regulates inﬂammation responses in as-
trocytes and plays an important role in the pathogenesis of depression and that UCP2 may be a pro-
mising therapeutic target for depression.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Major depressive disorder (MDD) is a major cause of disability
that affects approximately 16% of the world's population [1] and
has been characterized to associate with activated oxidative stress
[2], mitochondrial dysfunction [3], reduced neurogenesis [4] and
chronic inﬂammation [5]. In the brain, astrocytes, the most nu-
merous and versatile of all types of glial cells, are responsible for
the production of reactive oxygen species (ROS) and pro-in-
ﬂammatory cytokines, such as interleukin (IL)-1β that has been
demonstrated to be a crucial factor in the induction of depressive
symptomatology [6,7]. First, the expression level of IL-1β is con-
sistently increased in the blood or the brain of the depressedB.V. This is an open access article u
of Neurogeneration, Depart-
y, Nanjing, Jiangsu 210029,patients, which is clearly correlated with the severity of disease
[8]. Second, administration of exogenous IL-1β, either peripherally
or directly into the brain, produces depressive-like symptoms
[9,10], whereas blockade of the IL-1 receptor inhibits these stress-
like effects [11]. Third, antidepressant treatment can attenuate
depressive-like behavior through inhibiting the function of IL-1β
[12].
IL-1β production is tightly controlled by inﬂammasome, an
intracellular multiprotein complex that consists of nod-like re-
ceptor protein (NLRP), adaptor protein ASC and procaspase-1 [13].
Among the NLR family, the NLRP3 inﬂammasome is the most ex-
tensively studied and best understood member [14]. It is well
known that NLRP3 inﬂammasome can be activated by a variety of
danger signals, such as pathogen-associated molecular patterns
[15] and danger-associated molecular patterns [16] and the pro-
duction of ROS has been demonstrated to act as a common cellular
signal upstream of NLRP3 activation [17]. ROS promotes the dis-
sociation of thioredoxin-interacting protein (TXNIP) from thior-
edoxin and allows TXNIP to bind to NLRP3, and subsequentlynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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recognized that the NLRP3 inﬂammasome is implicated in the
pathophysiology of a number of diseases, including depression
[19], type 2 diabetes [20], rheumatoid arthritis [21] and Alzhei-
mer's disease [22]. Thus, the functional manipulation of the NLRP3
inﬂammasome has been thought to be a promising therapeutic
strategy for these diseases [23,24]. However, it remains undeﬁned
whether the ROS-TXNIP-NLRP3 signal pathway mediates the ac-
tivation of the NLRP3 inﬂammasome in astrocytes.
The main source of cellular ROS is mitochondria [25]. Amongst
the uncoupling proteins (UCP) identiﬁed in the inner membrane of
mitochondria, UCP2 is ubiquitously expressed and plays a crucial
role in controlling the production of cellular ROS [26]. Recent
studies have shown that UCP2 is associated with neurodegenera-
tive diseases such as Parkinson's disease [27], Alzheimer's disease
[28] and stroke [29] and its neuroprotective function is likely
mediated through restricting the production of ROS and inhibiting
inﬂammation and cell death. Since astrocytes play crucial roles in
the development of depression and are the major sites for ROS
production as well as innate immune responses [6], we thus hy-
pothesize that astrocytic UCP2 might regulate NLRP3 inﬂamma-
some activation and participate in the pathogenesis of depression.
In the present study, we prepared chronic mild stress (CMS) model
with UCP2 knockout mice so as to investigate the role of UCP2 in
depression and cultured primary astrocytes to reveal the under-
lying mechanism for UCP2-regulated neuroinﬂammation. It was
found that UCP2 knockout exacerbated depressive-like behaviors,
impaired neurogenesis, and the loss of astrocytes in CMS-induced
model of depression. Furthermore, UCP2 deﬁciency aggravated
NLRP3 inﬂammasome activation and enhanced ROS-TXNIP-NLRP3
signaling in astrocytes. These ﬁndings suggest that UCP2 may be a
potential therapeutic target for depression.2. Materials and methods
2.1. Mice
UCP2 / mice on a C57/B6 background were originally ob-
tained from Dr. Chenyu Zhang (School of Life Science, Nanjing
University, Nanjing, China). UCP2 / mice and their littermate
wild-type controls were bred and maintained in the Animal Re-
source Centre of the Faculty of Medicine, Nanjing Medical Uni-
versity and age-matched adult male mice (2 month old) used for
the experiments. All experiments were carried out in strict ac-
cordance with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals.
2.2. Chronic mild stress (CMS) procedure
Both genotypic male mice were individually housed and sub-
jected to 5 weeks of stressors, which were mild and unpredictable
in nature, duration, and frequency. Stressors included inversion of
day/night light cycle, soiled cage bedding, 45° tilted cage, restraint,
overnight food and water deprivation, and pairing with another
stressed animal. Sucrose preference and body weight of each an-
imal were evaluated weekly until the end of the CMS. The physical
state was measured weekly over the entire 5-week stress period
using a scale from 1 to 3: a health state was noted 3, a damaged
state with piloerection and/or dirty fur noted 1, and an inter-
mediate state noted 2 [30].
2.3. Sucrose preference test
Sucrose preference test was carried out weekly until the end of
the CMS. Mice were water deprived for 12 h, and then wereallowed to drink from two bottles for 10 h: one contained 1% su-
crose solution and the other only tap water. To prevent the pos-
sible effect of side-preference in drinking behavior, the positions of
the bottles in the cage were switched after the ﬁrst 5 h. The con-
sumption of tap water, sucrose solution, and total intake of liquids
was estimated simultaneously in the control and experimental
groups by weighing the bottles. The preference for sucrose was
measured as a percentage of the consumed sucrose solution re-
lative to the total amount of liquid intake.
2.4. Tail suspension test
Mice tails were wrapped with tape from the base to the tip,
covering about 4/5 of its length and ﬁxed upside down on the
hook. The immobility time of each mouse was recorded over a
6-min period. Mice were considered immobile only when they
hung passively and completely motionless. The time of immobility
of the tail suspended mice during the last 4 min was measured
with TailSuspScan™ (Clever Sys Inc., USA).
2.5. Forced swim test
Mice were individually forced to swim in an open cylindrical
container (diameter, 15 cm; height, 25 cm), containing 14 cm of
water at room temperature (about 2271 °C) for 6 min. A mouse
was judged to be immobile when it ﬂoated in an upright position,
and made only small movements to keep its head above water. The
duration of immobility was recorded during the last 4 min of the
6-min testing period by TailSuspScan™ (Clever Sys Inc., USA). The
immobility observed in this test is considered to reﬂect a state of
despair.
2.6. Detection of ROS
In situ detection of ROS was performed as described previously
[31]. Dihydroethidium (Molecular Probes) was used to investigate
the local in situ production of ROS. An intravenous injection of
200 μl dihydroedithium (DHE; stock solution, 100 mg/ml in DMSO,
diluted 1:100 with sterile saline before injection) was adminis-
tered through the caudal vein. Three hours after DHE injection,
mice were overdosed with dimethyl ether and transcardially per-
fused with 4% paraformaldehyde (0.1% glutaraldehyde and 15%
picric acid in phosphate buffer). After postﬁxing overnight in
paraformaldehyde without glutaraldehyde, sections at 30 mmwere
cut through the hippocampus using a Leica freezing microtome.
Images were observed and photos were taken under a ﬂuorescent
microscope. The intensity of ﬂuorescence was determined by a
multimode reader (Vario Skan Flash, 3001, Thermo Scientiﬁc)
under an emission wavelength at 530 nm and excitation wave-
length at 485 nm.
Intracellular ROS was measured with the ROS-speciﬁc ﬂuor-
escent probe 20, 70-dichlorodihydroﬂuorescein diacetate, acetyl
ester (CM-H2DCFDA; Invitrogen, USA). Astrocytes were incubated
with 20 μM H2DCF-DA for 30 min at 37 °C and washed twice with
PBS. The cells then were stained with Hoechst 33342 for 10 min.
Images were observed and photos were taken under a confocal
microscope (Axiovert LSM510; Carl Zeiss Co.). Fluorescence was
measured at OD485–530 using a multi-well spectrophotometer.
2.7. Immunohistochemistry and quantiﬁcation of staining
Following the behavioral tests, the mice were given bromo-
deoxyuridine (BrdU) intraperitoneally (450 mg/kg every 2 h,
Sigma, US) according to the previous procedures [30]. For analysis
of cell proliferation, six mice were killed and transcardially per-
fused (0.1 M cold phosphate-buffered saline for 5 min followed by
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After perfusion, Brain samples were collected and post- ﬁxed in 4%
PFA at 4 C overnight. They were transferred to 20% sucrose in
phosphate-buffered saline (PBS) overnight and then to 30% su-
crose overnight till the brain sunk to the bottom of the tube. Serial
sections of the brains were cut (30-μm sections) through each
entire hippocampus using a freezing microtome. All sections were
collected in six separate series. For immunohistochemistry and
immunoﬂuorescence, free-ﬂoating sections were placed in a
blocking solution consisting of 5% bovine serum albumin (BSA)
and 0.3% triton X-100 in 0.01 mol/L PBS for 2 h. For BrdU im-
munohistochemistry, sections were incubated in anti-mouse BrdU
(1:2500; MAB3510, Millipore, USA) overnight at 4 °C h and ap-
propriate anti-mouse secondary antibody for 1 h. Immunostaining
was visualized by using substrate-chromogen solution (DAB) for
10 min. For immunoﬂuorescence, sections were incubated with
anti-goat doublecortin (DCx, sc-8066, Santa Cruz Biotechnology,
USA), or anti- mouse glial ﬁbrillary acidic protein (GFAP, MAB360,
Millipore, USA) overnight at 4 °C and the appropriate ﬂuorescent
secondary antibody, donkey anti-goat IgG 488 Alexaﬂuore or
donkey anti-mouse IgG 488 Alexaﬂuore (1:200; Molecular Probes)
for 1 h. Images were observed and photos were taken under a
ﬂuorescent microscope. The immunostaining signals were quan-
titatively analyzed using the Optical Fractionator method with
Microbrightﬁeld Stereo-Investigator software (Stereo Investigator
software; Microbrightﬁeld). The total number of BrdU- positive
cells, DCx- positive cells and GFAP-positive astrocytes in entire
extent of hippocampus were counted from six samples per group.
2.8. Culture, transfection and treatment of mouse primary astrocytes
Mouse primary astrocytes were prepared as described pre-
viously [27]. Brieﬂy, neonatal mouse (P0–3) were killed by rapid
decapitation, the hippocampus was removed and separated from
meninges , and tissue was dissociated with 0.25% trypase (Am-
resco, Solon, OH) at 37 °C and terminated by Dulbecco's modiﬁed
Eagle's medium (Gibco-BRL, Rockville, MD) supplemented with
10% fetal bovine serum (Sigma, St Louis, MO). After centrifugation
at 1500 rpm for 5 min, the cell pellets were resuspended and
plated on a poly-lysine–treated ﬂask (Sigma, St Louis, MO). The
cultures were maintained at 37 °C in a humidiﬁed 5% CO2–95% air
atmosphere. Culture media were changed 24 h later to complete
medium and subsequently twice a week. The purity of astrocyte
was 495% as determined with GFAP immunocytochemistry.
Before experimental treatments, astrocytic cultures were pas-
saged once. Astrocytes were cultured at a conﬂuency of 70–80% in
24-well dishes and transfected with 1 μg of the full-length hu-
man UCP2 cDNA (pcDNA3.1-hUCP2) or the pcDNA3.1 empty
vector in OptiMEM (Gibco, USA) using X-tremeGENE HP DNA
Transfection Reagent (Roche, Switzerland) for 24 h. For the in-
duction of inﬂammasome activation, astrocytes were primed
with ultrapure lipopolysaccharide (100 ng / ml, Sigma, USA) for
24 h and then pulsed with 250 μg/ml monosodium urate (MSU,
Sigma, USA) for 6 h or 5 mM ATP (Sigma, USA) for 30 min. For
pharmacological measurements, the caspase-1 inhibitor z-YVAD-
zmk (10 μM, Tocris, UK), the ROS inhibitor (2 R,4 R)4-amino-
pyrrolidine-2, 4-dicarboxylate (APDC, 100 μM, Sigma, USA), or
the UCP2 inhibitor genipin (50 μM, Sigma, USA) was added to the
cell culture medium 1 h before LPS stimulation. The cell extracts
and precipitated supernatants were analyzed by ELISA and
immunoblotting.
2.9. Flow cytometry analysis
Mitochondria membrane potential was measured by ﬂuores-
cence levels upon staining with Mitotracker green (M7514,Invitrogen) and Mitotracker deep red (M22426, Invitrogen) at
50 nM for 30 min at 37 °C and according to the manufacturer's
instructions. Mitochondria-associated ROS levels were measured
by staining cells with MitoSOX (Invitrogen, USA) at 2.5 μM for
30 min at 37 °C. The cells were then washed with PBS and re-
suspended in cold PBS containing 1% FBS for ﬂow cytometric
analyses.
2.10. Reverse transcription and quantitative real-time PCR
Total RNA was extracted from cultured cells with Trizol reagent
(Invitrogen, USA). Reverse transcription PCR was carried out using
a TAKARA PrimeScript RT reagent kit and real-time PCR was
measured using a QuantiTect SYBR Green PCR kit (Qiagen, Ger-
many) with an ABI 7300 Fast Real-Time PCR System (Applied Bio-
systems, Foster City, CA). GAPDH was used as an internal control for
the real-time PCR ampliﬁcation. The sequences of primers for real-
time PCR analysis are as follows: GAPDH forward primer 5’-
CAAAAGGGTCATCTCC-3’ and reverse primer 5’-CCCCAGCAT-
CAAAGGTG-3’; UCP2 forward primer 5’-GCTGGTGGTGGTCGGAGAT-
3’ and reverse primer 5’-TGAAGTGGCAAGGGAGGT-3’; NLRP1 for-
ward primer 5’-CACTGCCCAAGATTGCTACA-3’ and reverse primer
5’-CTTCACTCAGCACCAGACCA-3’; NLRP3 forward primer 5’-
GTGGTGACCCTCTGTGAGGT-3’and reverse primer 5’-
TCTTCCTGGAGCGCTTCTAA-3’; NLRC4 forward primer 5’-CTA-
CATTGATGCTGCCTTGG-3’ and reverse primer 5’-ATCCGTCACTGCT-
CACACAG-3’; AIM2 forward primer 5’-CACCCTCATGGACCTACACTA-
3’and reverse primer 5’-CGTTGTTAGTAAATCAGCAGTTCT-3’.
2.11. Elisa
The concentration of IL-1β in the cell culture supernatant and
serum was measured by mouse IL-1β ELISA Kit (R&D, USA) ac-
cording to the manufacturer's instructions.
2.12. Immunoprecipitation
The total cell lysate prepared from astrocytes was incubated
with anti-TXNIP (40–3700, Invitrogen) or anti-NLRP3 antibodies
(AG-20B-0014-C100, Adipogen) followed by an incubation with
protein A/G plus agarose (Santa Cruz Biotechnology, USA) as de-
scribed previously [18] After washing the beads, the bound pro-
teins were eluted and analyzed by immunoblotting.
2.13. Immunoblotting
Immunoreactive bands were detected by enhanced chemilu-
minescence (ECL) plus detection reagent (Pierce, Rockford, IL) and
analyzed using an Omega 16ic Chemiluminescence Imaging Sys-
tem (Ultra-Lum, CA). The following primary antibodies were used:
goat anti-NLRP3 (sc-34410, Santa Cruz Biotechnology, USA), rabbit
anti-Caspase-1 (sc-514, Santa Cruz Biotechnology, USA), goat anti-
IL-1β (AF-401-NA, R&D, USA), rabbit anti-p65 (Ab536, Abcam,
USA), mouse anti-Histone3 (6388, Cell Signaling, USA), mouse
anti-TXNIP (K0205–3, MBL, USA) and goat anti-UCP2 (sc-6525,
Santa Cruz Biotechnology, USA).
2.14. Statistical analysis
All data are expressed as means 7 S.E.M. The differences with
different treatments and genotypes were determined by one-way
or two-way ANOVA, followed by the Tukey's post hoc test, and
were considered as statistically signiﬁcant at Po0.05.
Fig. 1. UCP2 knockout exacerbated CMS-induced depressive responses of mice. (A–E) body weight gain (A), sucrose preference (B), physical states (C), tail suspension test
(D) and forced swim test (E) in UCP2þ /þ and UCP2/ mice following 5 weeks of CMS. Data are represented as means7SEM. n¼18–24, *po0.05, **po0.01, ***po0.001 vs
corresponding control; #po0.05, ##po0.01 vs UCP2þ /þ CMS groups.
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3.1. UCP2 knockout exacerbates CMS-induced depressive behaviors
in mice
To study the role of UCP2 in depression, UCP2 knockout mice
were subjected to the CMS procedure and their depressive beha-
viors analyzed. UCP2 / mice exhibited a signiﬁcant decrease in
the sucrose preference and in body weight increase compared to
UCP2þ /þ mice after the CMS paradigm (Fig. 1A and B, Po0.05).
Although the CMS procedure signiﬁcantly impaired the physical
state in both genotypic mice, the deteriorative effect on the phy-
sical state was more remarkable in UCP2 / mice than that in
UCP2þ /þ mice (Fig. 1C, Po0.05). In both tail suspension and
forced swim tests, UCP2 knockout led to a signiﬁcant increase in
the duration of immobility following 5 weeks of CMS (Fig. 1D and
E). These data suggest that UCP2 deﬁciency enhances the pro-
gression of depression in adult mice.
3.2. UCP2 knockout aggravates the CMS-induced inhibition of
neurogenesis
To study the possible inﬂuence of ablating UCP2 on neuro-
genesis, we compared the cell proliferation of hippocampus in
wild-type and UCP2 KO mice. The CMS paradigm signiﬁcantly
reduced the number of BrdU-positive cells by 16% and 27% in the
hippocampus of wild-type and UCP2 / mice, respectively
(Fig. 2A and B). Similarly, the CMS signiﬁcantly decreased the total
number of DCx-positive cells in the dentate gyrus in both wild-
type and UCP2 / mice, but the reduction was more severe in
UCP2 KO mice than that in UCP2þ /þ mice (Fig. 2C and D). Fur-
thermore, after the CMS challenge, the number of astrocytes was
reduced more potently in UCP2 / mice than in wild-type mice
(Fig. 2E and F, Po0.05). These results demonstrate that UCP2
knockout aggravates the CMS-induced inhibition of neurogenesis
and the loss of astrocytes.3.3. UCP2 deﬁciency enhances the activation of NLRP3 inﬂamma-
some in the hippocampus in vivo and in astrocytes in vitro
As IL-1β is an important inﬂammatory factor involved in the
development of depression [9,32] and its production is tightly
controlled by the NLRP3 inﬂammasome [33] we next determined
the effect of UCP2 knockout on the expression of IL-1β and the
activation of the NLRP3 inﬂammasome in the hippocampus. We
found that UCP2 / mice displayed a marked increase in the
serum IL-1β compared with UCP2þ /þ mice after exposure to CMS
(Fig. 3A, Po0.01). The CMS procedure also markedly increased the
activation of NF-кB and enhanced the expression of NLRP3 in
UCP2 / mice compared with UCP2þ /þ mice (Fig. 3B and C,
Po0.05). Furthermore, the active caspase-1 and the matured IL-
1β were signiﬁcantly increased in the hippocampus of UCP2 /
mice compared to UCP2þ /þ mice (Fig. 3B and C, Po0.05) fol-
lowing the CMS challenge. These data demonstrate that UCP2
deﬁciency enhances the CMS-induced the activation of NLRP3
inﬂammasome in the hippocampus.
Astrocytes are the major sites contributing to the inﬂammatory
responses in the brain and play a crucial role in the pathogenesis
of depression [6]. We found that both UCP2 and NLRP3 are highly
expressed in astrocytes (Fig. 3D-F). Therefore, we then sought to
study the regulation of NLRP3 inﬂammasome by UCP2 in astro-
cytes. Astrocytes were isolated fromwild-type and UCP2 knockout
mice and treated with the NLRP3 inﬂammasome activators ATP
and MSU. Similar to the results obtained in the hippocampus, the
enhancements in the activation of NF-кB and caspase-1 and the
expression of NLRP3 and IL-1β after the treatment with ATP and
MSU were much more potent in astrocytes prepared from UCP2/
 KO mice than those from UCP2þ /þ mice (Po0.05) (Fig. 3G and
H). Consistently, the treatment with the UCP2 pharmacological
inhibitor genipin (50 μM) facilitated the activation of caspase-1
and expression of IL-1β in UCP2þ /þ astrocytes stimulated with
LPS plus MSU, but not in UCP2-/- astrocytes (Fig. 3I and J, Po0.05).
Furthermore, treatment with the caspase-1 inhibitor z-YVAD-fmk
Fig. 2. UCP2 deletion aggravated CMS-induced inhibition of neurogenesis and the loss of astrocytes in mice. (A-F) Immunohistochemical staining and stereological counts of
BrdUþ (A–B), DCxþ (C-D) and GFAPþ (E–F) cells in the s hippocampus of UCP2þ /þ and UCP2/ mice following 5 weeks of CMS. Data are represented as means7SEM. n¼6,
*po0.05, **po0.01, ***po0.001 vs corresponding control; #po0.05 vs UCP2þ /þ CMS groups.
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astrocytes, which conﬁrmed that the greater abundance of IL-1β
was the consequence of more caspase-1 activity (Fig. 3K). These
results demonstrate that, similar to the hippocampus, UCP2 deﬁ-
ciency also promotes the activation of NLRP3 inﬂammasome in
astrocytes.
3.4. The ROS-TXNIP-NLRP3 signaling pathway mediates the NLRP3
inﬂammasome activation in UCP2 knockout astrocytes
Our preceding data have strongly demonstrated that UCP2 is a
negative regulator of the NLRP3 inﬂammasome. To dissect the
underlying molecular mechanisms, we ﬁrst measured the func-
tional mitochondrial pool in wild-type and UCP2 KO astrocytes
using mitochondria-speciﬁc labels which are able to distinguishthe respiring (Mitotracker deep red) and total (Mitotracker green)
mitochondria. Treatments with LPS and MSU produced a greater
loss of mitochondrial membrane potential and increase in mi-
tochondrial volume in UCP2 KO than in wild-types (Fig. 4A–C,
Po0.05). As mitochondria are the main source of cellular ROS,
we then determined the effect of UCP2 KO on the production of
ROS in the hippocampus and in astrocytes. The CMS procedure
markedly augmented the ROS production in the hippocampus
and UCP2 / mice displayed a higher level of ROS compared to
WT mice as evaluated by the ﬂuorescence of DHE (Fig. 4D and E,
Po0.05). Similarly, UCP2 KO astrocytes generated more mi-
tochondrial ROS as detected by the ﬂuorescence of MitoSOX
(Fig. 4F, Po0.05) and intracellular ROS as measured by the
ﬂuorescence of CM-H2DCFDA (Fig. 4G and H, Po0.05) than wild-
type astrocytes.
Fig. 3. UCP2 deﬁciency enhanced the activation of NLRP3 inﬂammasome in hippocampus and in mouse astrocytes. (A) ELISA of serum Il-1β (n¼10/group). (B-C) Re-
presentative Immunoblot (B) and quantitative (C) analysis of nucelus p65, NLRP3, procaspase-1, caspase-1, proIL-1β, and Il-1β in the hippocampus of UCP2þ /þ and UCP2 /
mice (n¼4/group). (D-E) mRNA (D) and protein levels of UCP2 (E) in astrocyte and spleen (positive control) of UCP2þ /þ and UCP2/ mice. (F) Real-time PCR analysis of
mRNA levels of NLRP3, NLRP1, NLRC4 and AIM2 in astrocytes. (G–H) Representative Immunoblot (G) and quantitative (H) analysis of nucelus p65, NLRP3, procaspase-1,
caspase-1, proIL-1β, and Il-1β in astrocytes from UCP2þ /þ and UCP2/ mice. (I–J) Representative Immunoblot (I) and quantitative analysis (J) of NLRP3, procaspase-1,
caspase-1, proIL-1β, and Il-1β in lysates and supernatants of UCP2þ /þ and UCP2/ astrocytes incubated for 1 h with genipin (G, 50 mM), followed by stimulation with
LPSþMSU. (K) ELISA of Il-1β secretion by UCP2þ /þ and UCP2/ astrocytes incubated for 1 h with z-YVAD-fmk (z-YVAD; 10 mM), followed by stimulation with LPSþATP or
LPSþMSU. Data are represented as means7SEM from four independent experiments. *po0.05, **po0.01 vs corresponding control; #po0.05, ##po0.01.
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Fig. 4. ROS-TXNIP-NLRP3 signaling pathway contributed to the enhancement of NLRP3 inﬂammasome activation in UCP2 knockout astrocytes. (A–B) Astrocytes were
stimulated with LPSþMSU for 6 h and then stained with Mitotrackergreen and Mitotracker deep red for 30 min and analyzed by ﬂow cytometry (A). B, Quantiﬁcation of the
mitochondrial membrane potential. (C) Confocal microscopy of morphological changes in mitochondria monitored by staining with Mitotrackergreen. (D-E) UCP2 knockout
increased ROS production in vivo. D, Photos were taken at 600 magniﬁcation. Red color represents DEH and blue color represents nucleus. Scale bar¼22 mm. E, Quan-
tiﬁcation of the ﬂuorescence intensity of the DEH staining to assess ROS level in vivo (n¼6/group). (F-H) Astrocytes were stimulated with LPSþMSU for 6 h and then stained
with MitoSOX (F) or CM-H2DCFDA labeling (G–H) for 30 min and analyzed by ﬂow cytometry or confocal microscope. (I–J) Representative Immunoblot (I) and quantitative
analysis (J) of NLRP3, procaspase-1, caspase-1, proIL-1β, and Il-1β in the presence of ROS inhibitor (APDC, 100 mM). (K–L) Immunoprecipitation and immunoblot analysis of
the interaction of TXNIP with NLRP3 in the presence of ROS inhibitor (APDC, 100 mM). Data are represented as means7SEM from four independent experiments. **po0.01 vs
corresponding control; #po0.05, ##po0.01.
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Fig. 5. Rescue of UCP2 inhibited ROS production and NLRP3 inﬂammasome activation in mouse astrocytes. UCP2 / astrocytes were transfected with either full-length human
UCP2 cDNA plasmid (UCP2) or pcDNA3.1 empty vector (vector) for 24 h, and then stimulated with LPSþMSU. (A) The expression of UCP2 in UCP2þ /þ astrocytes and UCP2/
astrocytes transfected with either full-length human UCP2 cDNA plasmid (UCP2) or pcDNA3.1 empty vector (vector) for 24 h. (B-C) Confocal microscopy of morphological changes
in mitochondria monitored by staining with Mitotrackergreen (B) and quantiﬁcation of mitochondrial diameter (C). (D-E) Rescue of UCP2 inhibited ROS production in astrocytes.
D, Photos were taken by confocal. E, Quantiﬁcation of the ﬂuorescence intensity of the CM-H2DCFDA staining to assess intracellular ROS level. (F-G) Representative Immunoblot
(F) and quantitative analysis (G) of NLRP3, procaspase-1, caspase-1, proIL-1β, and Il-1β in lysates and supernatants of astrocytes. (H) Schematic layout of showing UCP2 knockout
aggravates major depressive disorder via enhancing NLRP3 inﬂammasome activation in mouse astrocytes. Data are represented as means7SEM from four independent
experiments. *po0.05, **po0.01 vs MSUþvector group.
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R.-H. Du et al. / Redox Biology (2016) 178–187186To determine whether UCP2 knockout-induced ROS production
contributed to the activation of NLRP3 inﬂammasome, the primary
cultures of astrocytes were treated with the ROS inhibitor APDC.
The APDC treatment signiﬁcantly abrogated the increase in IL-1β
secrestion and caspase-1 activation in UCP2 KO astrocytes treated
with LPS and MSU (Fig. 4I and J). It has been demonstrated that
TXNIP binds to and activates NLRP3 in ROS dependent manner
[18]. We then determined if UCP2 KO could alter the interaction
between TXNIP and NLRP3. As shown in Fig. 4K and L, UCP2 KO
resulted in a signiﬁcant increase in the TXNIP-NLRP3 association,
and this effect was abolished by APDC treatment. These data
suggest that the function of UCP2 in regulating the NLRP3 in-
ﬂammasome activation is likely mediated through the ROS-TXNIP-
NLRP3 signaling pathway in astrocytes.
3.5. Transient expression of UCP2 rescues the mitochondrial injury,
ROS production and the NLRP3 inﬂammasome activation in astro-
cytes lacking UCP2
To further deﬁne the role of UCP2 in depression and the NLRP3
inﬂammasome activation as observed in the UCP2 KO mice, we
determined if transiently expressing UCP2 could reverse the de-
leterious effects of ablating UCP2 on the mitochondrial function,
ROS production and the NLRP3 inﬂammasome activation in as-
trocytes. UCP2 was transiently expressed in astrocytes isolated
from UCP2 KO mice at a level similar to the expression of en-
dogenous UCP2 (Fig. 5A). Increased UCP2 expression dramatically
alleviated the swollen mitochondria (Fig. 5B and C) and reduced
ROS production in UCP2 KO astrocytes (Fig. 5D and E). Expression
of UCP2 also attenuated NLRP3 expression, caspase-1 activation
and IL-1β secretion in response to LPS and MSU stimulation
(Fig. 5F and G). These data indicate the re-expression of UCP2
could protect astrocytes from the damage.4. Discussion
The most important ﬁnding presented here is that UCP2 is a
crucial regulator of the NLRP3 inﬂammasome in astrocytes. Acti-
vation of the NLRP3 inﬂammasome requires two signals [34]. The
ﬁrst signal is provided by microbial or endogenous molecules that
activate NF-κB to induce NLRP3 expression, which is a prerequisite
for inﬂammasome activation [15,35]. The second signal directly
activates the NLRP3 inﬂammasome to induce the activation of
caspase-1, leading to the maturation of the proinﬂammatory cy-
tokines IL-1β and IL-18 [36]. In the present study, we found that
the activation of NF-κB and the expression of NLRP3 were sig-
niﬁcantly higher in UCP2 / mice than UCP2þ /þ mice after the
exposure to CMS. We also observed that, compared with UCP2þ /þ
mice, UCP2/ mice displayed a signiﬁcant increase in the acti-
vation of caspase-1 and the maturation of IL-1β following CMS.
These data indicate that UCP2 deﬁciency enhances both the
priming and the activation of the NLRP3 inﬂammasome.
Our study further reveals the molecular mechanism underlying
the function of UCP2 in regulating the activation of NLRP3 in-
ﬂammasome in astrocyets. The production of ROS is believed to be a
common activator of the NLRP3 inﬂammasome [37]. However, the
role of physical association of NLRP3 with TXNIP in the ROS-de-
pendent activation of NLRP3 inﬂammasome has been contradictory
[38,39]. In this study, we found that UCP2 knockout not only in-
creased the ROS production but also promoted the TXNIP-NLRP3
association in mouse astrocytes. Furthermore, treatment with the
ROS inhibitor APDC almost abolished the association of TXNIP with
NLRP3 and the activation of NLRP3 inﬂammasome in UCP2 knock-
out astrocytes. These data demonstrate that the function of UCP2 in
regulating the activation of NLRP3 inﬂammasome is mediatedthrough controlling the production of ROS and the association of
NLRP3 with TXNIP in astrocytes. This mechanism is also consistent
with other reports demonstrating the role of ROS and the TXNIP-
NLRP3 interaction in the activation of the NLRP3 inﬂammasomes in
other cell types including primary rat hepatocytes , endothelial cells
[40] and mouse beta cells [18]. Taken together, these ﬁndings in-
dicate that the ROS-TXNIP-NLRP3 signal pathway contributes to the
modulation of the NLRP3 inﬂammasome activation by UCP2.
Another important ﬁnding described here is that we provide
strong evidence further indicating that UCP2 plays an important
role in the pathogenesis of depression. We used UCP2 / mice to
establish a CMS-induced anhedonia model of depression and
found that UCP2/ mice displayed the lower sucrose preference
(anhedonia) and bodyweight. UCP2 knockout mice also had re-
markable deterioration of the physical state and a signiﬁcant in-
crease in the duration of immobility. These data, together with our
previous report [41], indicate that UCP2 knockout aggravated de-
pressive-like behaviors. Consistent with the observed deleterious
effects on the behaviors, we found that UCP2 knockout reduced
the ability of neurogenesis in the hippocampus and enhanced the
loss of astrocytes. These data suggest that both the impaired
neurogenesis and the reduced astrocytes may contribute to the
depressive behaviors observed in UCP2 KO mice.
Growing evidence indicates that astrocytes cannot be just con-
sidered as passive supportive cells deputed to preserve neuronal
activity and survival, but rather they are involved in a striking
number of active functions that are critical to the performance of
the central nervous system [42]. Recently, animal studies and
postmortem brain analyses of patients with depression implicated
glial dysfunction in MDD pathophysiology [43,44]. Astrocytes-
mediated inﬂammation plays an important role in the pathogenesis
of depression [45] and neurodegenerative diseases such as Alzhei-
mer Disease [46], Parkinson Disease [27] and stroke [47]. UCP2
knockout enhanced the activation of NLRP3 inﬂammasome and
increased the production of IL-1β in astrocytes, indicating that as-
trocytic UCP2 is involved in the development of the NLRP3 in-
ﬂammasome-driven inﬂammatory diseases, including depression.
In conclusion, our study demonstrates that UCP2 knockout
aggravates depressive-like behaviors, impairs neurogenesis, and
promotes the loss of astrocytes in CMS-induced model of de-
pression. Furthermore, UCP2 deﬁciency exacerbates NLRP3 in-
ﬂammasome activation and enhances ROS-TXNIP-NLRP3 signaling
in astrocytes (Fig. 5H). Collectively, our ﬁndings reveal that UCP2
negatively regulates inﬂammation responses in astrocytes and
plays an important role in the pathogenesis of depression and that
UCP2 may be a promising therapeutic target for depression.Conﬂicts of interest
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